Angiotech Pharmaceuticals, Inc.

Published Date: 14/06/2011
Category: Drug Delivery & Devices

Research Report Decription

Angiotech Pharmaceuticals, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Angiotech Pharmaceuticals, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Angiotech Pharmaceuticals, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Angiotech Pharmaceuticals, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Angiotech Pharmaceuticals, Inc.
• Intelligence on Angiotech Pharmaceuticals, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Angiotech Pharmaceuticals, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Angiotech Pharmaceuticals, Inc. and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Angiotech Pharmaceuticals, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Angiotech Pharmaceuticals, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Angiotech Pharmaceuticals, Inc.

Paper Highlights:

Angiotech Pharmaceuticals (Angiotech) is a specialty pharmaceutical and medical device company. It is engaged in the discovery, development, and marketing of innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. The company primarily operates in the US. It is headquartered in Vancouver, Canada and employed 1,350 people as of December 31, 2009. The company recorded revenues of $279.7 million during the financial year (FY) ended December 2009, a decrease of 1.3% over FY2008. The operating profit of the company was $23.1 million in FY2009, as compared to an operating loss of $671.2 million in FY2008. The net loss was $22.9 million in FY2009, as compared to a net loss of $741.2 million in FY2008.